Przemówienie Dr Ricka Doblina, Ph.D. założyciela i dyrektora wykonawczego Multidisciplinary Association for Psychedelic Studies (MAPS) na temat postępów fazy 3 klinicznych badań nad postępem 3 fazy klinicznych badań nad terapią przy użyciu MDMA w leczeniu zespołu stresu pourazowego (PTSD). Dodatkowo, rozmaite aktualności na temat innych inicjatyw naukowych prowadzonych w MAPS (2019).
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Brak komentarzy